Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Evaxion A/S changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 10 | 9 | −1 |
| Shares | 133.7K | 447.2K | +313.5K (+234.4%) |
| Value | $115.9K | $314.2K | +$198.3K (+171.2%) |
New holders (3)
Institutions that held Evaxion A/S at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| LM Advisors LLC | 337,336 | $231.3K | 0.05% |
| Citadel Advisors LLC | 24,630 | $16.9K | 0.00% |
| Renaissance Technologies LLC | 14,000 | $10.0K | 0.00% |
Sold out (4)
Institutions that held Evaxion A/S at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| AE Wealth Management LLC | 48,633 | $40.5K |
| Susquehanna International Group, LLP | 32,774 | $28.2K |
| Two Sigma Securities, LLC | 15,188 | $12.7K |
| Morgan Stanley | 3,446 | $2.87K |